{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-24-000035","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.992436+00:00","generated_at":"2026-06-03T04:36:28.968967+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"10x Genomics Q1: revenue up 5% to $141M, net loss widens to $59.9M; guidance reaffirmed","bullets":["Revenue of $141.0M (+5% YoY); gross margin 66% vs 73% due to product mix shift to Xenium instruments.","Net loss widened to $59.9M from $50.7M; operating loss $61.5M vs $52.0M.","FY2024 revenue guidance maintained at $670M-$690M, representing 8-12% growth over FY2023.","Shipped Visium HD for spatial discovery, GEM-X single cell technology, and Xenium cell segmentation products.","Operating expenses up 3% to $154.4M; stock-based compensation declined to $36.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-24-000035","json":"https://secwatch.observer/filing/0001770787-24-000035.json","markdown":"https://secwatch.observer/filing/0001770787-24-000035.md","text":"https://secwatch.observer/filing/0001770787-24-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000035/0001770787-24-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000035/txg-20240430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:36:28.968967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8e28852755825a52fff3dd3c2800828f633e9ae9","claim":"10x Genomics, Inc. reported first quarter ended March 31, 2024 results: revenue $141.0 million, net income -$59.9 million. Guidance reaffirmed.","evidence_excerpt":"Revenue was $141.0 million for the first quarter of 2024, a 5% increase from $134.3 million for the corresponding prior year period. Gross margin was 66% for the first quarter of 2024, as compared to 73% for the corresponding prior year period. The decrease in gross margin was primarily due to change in product mix driven by Xenium instruments. Operating expenses were $154.4 million for the first quarter of 2024, a 3% increase from $150.4 million for the corresponding prior year period. This increase was driven by higher legal expenses and costs for facilities and information technology partially offset by lower personnel expenses, including stock-based compensation. Operating loss was $61.5 million for the first quarter of 2024, as compared to $52.0 million for the corresponding prior year period. Operating loss includes $36.1 million of stock-based compensation for the first quarter of 2024, as compared to $42.1 million of stock-based compensation for the corresponding prior year per","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000035/0001770787-24-000035-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$141.0 million"},{"label":"Net income","value":"-$59.9 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}